Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label...
28 insider purchases on record · latest filing 2026-04-01.
Insiders have also filed 82 sale transactions at CRIS.